Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

• Chad J. Swanson,
• Yong Zhang,
• Shobha Dhadda,
• Jinping Wang,
• June Kaplow,
• Robert Y. K. Lai,
• Lars Lannfelt,
• Heather Bradley,
• Martin Rabe,
• Akihiko Koyama,
• Larisa Reyderman,
• Donald A. Berry,
• Scott Berry,
• Robert Gordon,
• Lynn D. Kramer,
• Jeffrey L. Cummings

Affiliations

Chad J. Swanson

Eisai Inc.

Yong Zhang

Eisai Inc.

Shobha Dhadda

Eisai Inc.

Jinping Wang

Eisai Inc.

June Kaplow

Eisai Inc.

Robert Y. K. Lai

Eisai Ltd.

Lars Lannfelt

BioArctic AB

Heather Bradley

Eisai Inc.

Martin Rabe

Eisai Inc.

Akihiko Koyama

Eisai Inc.

Larisa Reyderman

Eisai Inc.

Donald A. Berry

Berry Consultants, LLC

Scott Berry

Berry Consultants, LLC

Robert Gordon

Eisai Ltd.

Lynn D. Kramer

Eisai Inc.

Jeffrey L. Cummings

Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas